Your browser does not support javascript:   Search for gard hereSearch for news-and-events here.


Genetic and Rare Diseases Information Center (GARD)

Print friendly version

Dense deposit disease

Other Names for this Disease
  • DDD
  • Glomerulonephritis membranoproliferative type 2
  • Membranoproliferative glomerulonephritis type 2
  • Membranoproliferative glomerulonephritis type II
  • Mesangiocapillary glomerulonephritis type 2
More Names
See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.


Newline Maker

How might dense deposit disease be treated?

There is currently no specific treatment for dense deposit disease (DDD), but therapies are available to help slow the progression of the condition through aggressive blood pressure control and reduction of proteinuria. Both angiotensin-converting enzyme (ACE) inhibitors and angiotensin II type-1 receptor blockers (ARBs) can be used to decrease the amount of protein in the urine and improve kidney function. These drugs may also limit the infiltration of white blood cells into the kidney. If hyperlipidemia (increased lipid in the blood stream) is present, lipid-lowering drugs may be used to reduce long-term risks of atherosclerosis. These drugs may also delay progression of kidney disease. Steroid therapy was widely used in the past, but more recent studies have shown that it is probably not effective for DDD. Steroid therapy is effective in a form of glomerulonephritis called juvenile acute non-proliferative glomerulonephritis (JANG), which is sometimes confused with DDD.[1]

People with DDD who develop end-stage renal disease typically need peritoneal dialysis or hemodialysis. Kidney transplant may be an option for some individuals; however, DDD will still develop in virtually all transplanted kidneys and about half of transplants will ultimately fail. There is some evidence that the likelihood of transplant failure due to recurrent DDD decreases with time.[1]
Last updated: 2/24/2014

  1. Dense Deposit Disease. NORD. July 28, 2010; Accessed 4/20/2012.

Management Guidelines

  • GeneReviews provides current, expert-authored, peer-reviewed, full-text articles describing the application of genetic testing to the diagnosis, management, and genetic counseling of patients with specific inherited conditions. Click on the link to view the article on this topic.

Clinical Trials & Research for this Disease

  • lists trials that are studying or have studied Dense deposit disease. Click on the link to go to to read descriptions of these studies.
  • The North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) is a research effort organized in 1987 that hopes to register and follow greater than 80% of the children receiving renal allografts in North America, and study the clinical course and natural history of patients with renal dysfunction and to continue following these patients as they move among the end-stage renal disease (ESRD) therapeutic modalities, thus allowing the NAPRTCS to become a complete ESRD patient data system.